Peripheral edema associated with calcium channel blockers: Incidence and withdrawal rate - A meta-analysis of randomized trials

Journal of Hypertension

Volumn 29, Issue 7, 2011, Pages 1270-1280

  Makani, Harikrishna ^a   Bangalore, Sripal ^b   Romero, Jorge ^a   Htyte, Nay ^a   Berrios, Ronaldo S ^a   Makwana, Hetal ^a   Messerli, Franz H ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

calcium channel blockers; hypertension; peripheral edema

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; CILAZAPRIL; DILTIAZEM; DILTIAZEM PLUS ENALAPRIL MALEATE; ENALAPRIL; ENALAPRIL MALEATE PLUS FELODIPINE; EPLERENONE; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; MEPIRODIPINE; METOPROLOL; MIBEFRADIL; NIFEDIPINE; NISOLDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; UNINDEXED DRUG; ZOFENOPRIL;

CLINICAL EVALUATION; CLINICAL TRIAL; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION;

EID: 79958773038     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283472643     Document Type: Review

References (120)

1. Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol 2001; 38:642-650. (Pubitemid 32868236)
2. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15:932-940. (Pubitemid 35217397)
3. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 2002; 4:479-482.
4. US Food and Drug Administration. Available at: http:// www.accessdata.fda.gov/drugsatfda-docs/nda/97/19787- S013-Norvasc.pdf Accessed January 2010.
5. Littlejohn TW3rd, Majul CR, Olvera R, Seeber M, KobeM, Guthrie R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebocontrolled, parallel-group, 4-4 factorial study. Postgrad Med 2009; 121:5-14.
6. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29:563-580. (Pubitemid 47028551)
7. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. (Pubitemid 41265663)
8. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. (Pubitemid 38781102)
9. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372. (Pubitemid 30487492)
10. Schrader J, Salvetti A, Calvo C, Akpinar E, Keeling L, Weisskopf M, et al. The combination of amlodipine/valsartan 5/160mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract 2009; 63:217-225.
11. Higgins JP, Altman DG. Assessing risk of bias in included studies. In: Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane Book Series. John Wiley & Sons, Ltd: Chichester, UK, 2008. doi: 10.1002/9780470712184. ch. 8.
12. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326:219. (Pubitemid 36143396)
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. (Pubitemid 17189972)
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
16. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431. (Pubitemid 35340538)
17. Opie LH, Muller FO, Myburgh DP, Rosendorff C, Sareli P, Seedat YK, et al. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators. Am J Hypertens 1997; 10:250-260. (Pubitemid 27128267)
18. Bittar N. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group. Clin Ther 1997; 19:954-962. (Pubitemid 27508930)
19. Carr AA, Bottini PB, Feig P, Prisant LM, Mulligan S, Devane JG, et al. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. Am J Cardiol 1992; 69:28E-32E.
20. Cherubini A, Fabris F, Ferrari E, Cucinotta D, Antonelli Incalzi R, Senin U. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 37:203-212. (Pubitemid 37162859)
21. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. Am J Hypertens 1995; 8:87-89.
22. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-tomoderate hypertension. J Hum Hypertens 2003; 17:425-432. (Pubitemid 36722208)
23. Chrysant SG, Sugimoto DH, Lefkowitz M, Salko T, Khan M, Arora V, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press Suppl 2007; 1:10-17. (Pubitemid 46705167)
24. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8- week factorial efficacy and safety study. Clin Ther 2008; 30:587-604. (Pubitemid 351680489)
25. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group. Am J Med 1989; 86 (4A):94-97.
26. Cushman WC, Cohen JD, Jones RP, Marbury TC, Rhoades RB, Smith LK. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 1998; 11 (1 Pt 1):23-30. (Pubitemid 28083148)
27. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study - the EX-EFFeCTS Study. J Am Soc Hypertens 2008; 2:294-302.
28. Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007; 9:742-750.
29. Emeriau JP, Knauf H, Pujadas JO, Calvo-Gomez C, Abate G, Leonetti G, et al. A comparison of indapamide SR 1.5mg with both amlodipine 5mg and hydrochlorothiazide 25mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19:343-350. (Pubitemid 32116287)
30. Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2008; 30:482-498. (Pubitemid 351483926)
31. Fagan TC, Haggert BE, Liss C. Efficacy and tolerability of extendedrelease felodipine and extended-release nifedipine in patients with mildto- moderate essential hypertension. Clin Ther 1994; 16:634-646. (Pubitemid 24321692)
32. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press Suppl 2007; 2:19-24.
33. Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, et al. A dose-response trial of once-daily diltiazem. Am Heart J 1992; 123 (4 Pt 1):1022-1026.
34. Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, et al. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCl, in mature and elderly hypertensive patients. Clin Ther 1994; 16:209-221. (Pubitemid 24321658)
35. Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009; 23:479-489.
36. Fletcher AE, Bulpitt CJ, Chase DM, Collins WC, Furberg CD, Goggin TK, et al. Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. Hypertension 1992; 19 (6 Pt 1):499-507.
37. Fogari R, Mugellini A, Derosa G. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8:139-144. (Pubitemid 350148451)
38. Franco RJ, Goldflus S, McQuitty M,Oigman W. Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. Blood Press Suppl 2003; 2:41-47. (Pubitemid 38112144)
39. Frick MH, McGibney D, Tyler HM. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225:101-105. (Pubitemid 19119714)
40. Frishman WH, Zawada ET Jr, Smith LK, Sowers J, Swartz SL, Kirkendall W, et al. Comparison of hydrochlorothiazide and sustained-release diltiazem for mild-to-moderate systemic hypertension. Am J Cardiol 1987; 59:615-623. (Pubitemid 17047331)
41. Glasser SP, Jain A, Allenby KS, Shannon T, Pride K, Pettis PP, et al. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group. Clin Ther 1995; 17:12-29.
42. Glasser SP, Neutel JM, Gana TJ, Albert KS. Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. Am J Hypertens 2003; 16:51-58. (Pubitemid 36078591)
43. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997; 79:431-435. (Pubitemid 127440407)
44. Graney WF. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension. Am J Med 1992; 93 (2A): 56S-64S
45. Hall WD, Reed JW, Flack JM, Yunis C, Preisser J. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. Arch Intern Med 1998; 158:2029-2034. (Pubitemid 28465628)
46. Hart W, Holwerda NJ. Barnidipine, a novel calcium antagonist for oncedaily treatment of hypertension: a multicenter, double-blind, placebocontrolled, dose-ranging study. Dutch Barnidipine Multicenter Study Group. Cardiovasc Drugs Ther 1997; 11:637-643.
47. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee. BMJ (Clin Res Ed) 1988; 296:468-472.
48. Hermans L, Deblander A, De Keyser P, Scheys I, Lesaffre E, Westelinck KJ. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. Br J Clin Pharmacol 1994; 38: 335-340. (Pubitemid 24314688)
49. Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003; 163:1543-1548. (Pubitemid 36835098)
50. Holtzman JL, Abrams A, Cutler R, Hamilton B, Kirkendall WM, Neri G, et al. Multicenter comparison of once- and twice-daily isradipine to hydrochlorothiazide for the treatment of hypertension in elderly patients. Clin Pharmacol Ther 1990; 48:590-597.
51. Isles CG, Kitchin NR. A randomised double-blind study comparing nifedipine GITS 20mg and bendrofluazide 2.5mg administered once daily in mild-to-moderate hypertension. J Hum Hypertens 1999; 13:69-73. (Pubitemid 29042148)
52. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17:495-501. (Pubitemid 38726163)
53. A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. The United Kingdom Lacidipine Study Group. J Cardiovasc Pharmacol 1991; 17 (Suppl 4):S27-S30.
54. James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16:605-610. (Pubitemid 35021369)
55. Jensen HA. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A 1992; 14:1095-1110.
56. Jern S, Hansson L, Schersten B, Kullman S, Sorensen S, Dahlof B, et al. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group. J Cardiovasc Pharmacol 1991; 18 (Suppl 3):S7-S8.
57. Karch FE, Pordy R, Benz JR, Carr A, Lunde NM, Marbury T, et al. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group. Clin Ther 1997; 19:1368-1378. (Pubitemid 28133274)
58. Ke Y, Zhu D, Hong H, Zhu J, Wang R, Cardenas P, et al. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin 2010; 26:1705-1713.
59. Kelly JG, Devane JG, Geoghegan B. Pharmacokinetic properties and antihypertensive efficacy of once-daily diltiazem. J Cardiovasc Pharmacol 1991; 17:957-963.
60. Kloner RA, Weinberger M, Pool JL, Chrysant SG, Prasad R, Harris SM, et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol 2001; 87:727-731.
61. Koylan N, Acarturk E, Canberk A, Caglar N, Caglar S, Erdine S, et al. Effect of irbesartan monotherapy compared with ACE inhibitors and calciumchannel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study. Blood Press Suppl 2005; 1:23-31. (Pubitemid 41015710)
62. Kuschnir E, Bendersky M, Resk J, Panart MS, Guzman L, Plotquin Y, et al. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 2004; 43:300-305. (Pubitemid 38129692)
63. Leonetti G. Comparative study of lacidipine and nifedipine SR in the treatment of hypertension: an Italian multicenter study. The Northern Italian Study Group of Lacidipine in Hypertension. J Cardiovasc Pharmacol 1991; 17 (Suppl 4):S31-S34.
64. Liedholm H, Melander A. A placebo-controlled dose-response study of felodipine extended release in hypertensive patients. J Cardiovasc Pharmacol 1989; 14:109-113. (Pubitemid 19158082)
65. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens 2006; 19:113-121. (Pubitemid 43217045)
66. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003; 12:160-167. (Pubitemid 36874765)
67. Malacco E, Vari N, Capuano V, Spagnuolo V, Borgnino C, Palatini P. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003; 25:2765-2780. (Pubitemid 37521249)
68. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007; 25:2168-2177. (Pubitemid 47476316)
69. Marin-Iranzo R, de la Sierra-Iserte A, Roca-Cusachs A, Olivan-Martinez J, Redon-Mas J, Luque-Otero M, et al. Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg. Rev Clin Esp 2005; 205:418-424. (Pubitemid 41631643)
70. Massie BM, Chrysant SG, Jain A, Weir M, Weiss R, Korrin I. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. Clin Cardiol 1997; 20:562-568.
71. McClennen W, Wilson T. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group. Clin Invest Med 1998; 21:142-150. (Pubitemid 28306350)
72. McMahon FG, Reder RF. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. The Verapamil-SR Study Group. J Clin Pharmacol 1989; 29:1003-1007. (Pubitemid 20038080)
73. Mehta JL, Lopez LM, Vlachakis ND, Gradman AH, Nash DT, O'Connell MT, et al. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Am Heart J 1993; 125:1704-1710. (Pubitemid 23169487)
74. Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. Am J Hypertens 1998; 11 (3 Pt 1):322-327. (Pubitemid 28186744)
75. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86:1182-1187.
76. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8:571-581; quiz 582-583.
77. Millar-Craig M, Shaffu B, Greenough A, Mitchell L, McDonald C. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003; 17:799-806. (Pubitemid 37441438)
78. Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin Ther 2008; 30:1618-1628.
79. New sustained-release nifedipine formulation in treatment of essential hypertension. Unidipin Cooperative Study Group. J Cardiovasc Pharmacol 1992; 19:349-353.
80. Neldam S, Edwards C. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006; 15:151-160.
81. Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. Am J Geriatr Cardiol 2006; 15:142-150.
82. Ongtengco I, Morales D, Sanderson J, Lu ZR, Beilin LJ, Burke V, et al. Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two 'missed doses': a randomised, double-blind comparative trial in Asian patients. J Hum Hypertens 2002; 16:805-813. (Pubitemid 36007934)
83. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens 1991; 9:1097-1104.
84. Palatini P, Malacco E, Fogari R, Carretta R, Bonaduce D, Bertocchi F, et al. A multicenter, randomized double-blind study of valsartan/ hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. J Hypertens 2001; 19:1691-1696. (Pubitemid 32783789)
85. Pittrow DB, Antlsperger A, Welzel D, Wambach G, Schardt W, Weidinger G. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. Cardiovasc Drugs Ther 1997; 11:619-627. (Pubitemid 28041033)
86. Poisson P, Bauer B, Schueler E, Rangoonwala B. Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy. Curr Med Res Opin 1996; 13:445-456. (Pubitemid 26402688)
87. Pool PE, Nappi JM, Weber MA. Antihypertensive monotherapy with tablet (prompt-release) diltiazem: multicenter controlled trials. Cardiovasc Drugs Ther 1990; 4:1089-1096. (Pubitemid 20330473)
88. Pool J, Kaihlanen P, Lewis G, Ginsberg D, Oparil S, Glazer R, et al. Oncedaily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001; 15:495-498. (Pubitemid 32640266)
89. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47:1555-1569. (Pubitemid 350119781)
90. Redon-Mas J, Abellan-Aleman J, Aranda-Lara P, de la Figuera-von Wichmann M, Luque-Otero M, Rodicio-Diaz JL, et al. Antihypertensive activity of verapamil: impact of dietary sodium. The VERSAL Study Group. J Hypertens 1993; 11:665-671. (Pubitemid 23225210)
91. Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. J Cardiovasc Pharmacol 1991; 17 (Suppl 4):S38-43; discussion S44.
92. Romito R, Pansini MI, Perticone F, Antonelli G, Pitzalis M, Rizzon P. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003; 5:249-253. (Pubitemid 37098484)
93. Rosenthal J, Hittel N, Stumpe KO. Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: a multicenter, double-blind, placebo-controlled dose-finding study. Cardiovasc Drugs Ther 1996; 10:59-66.
94. Ruddy TD, Fodor JG. Nisoldipine CC and lisinopril alone or in combination for treatment of mild to moderate systemic hypertension. Canadian Nisoldipine CC Hypertension Trial Group. Cardiovasc Drugs Ther 1997; 11:581-590. (Pubitemid 27440248)
95. Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27:578-587. (Pubitemid 40835968)
96. Sharma A, Bagchi A, Kinagi SB, Sharma YK, Baliga VP, Bollmall C. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007; 29:2667-2676.
97. Schunkert H, Glazer RD, Wernsing M, Yen J, Macarie CE, Vintila MM, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy. Curr Med Res Opin 2009; 25:2655-2662.
98. Shepherd AM, Carr AA, Davidov M, Hamilton J, Schnaper H, Velasquez M, et al. Efficacy and safety of isradipine in hypertension. J Cardiovasc Pharmacol 1989; 13:580-585. (Pubitemid 19090113)
99. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
100. The treatment of mild hypertension study. A randomized, placebocontrolled trial of a nutritional-hygienic regimen along with various drug monotherapies. The Treatment of Mild Hypertension Research Group. Arch Intern Med 1991; 151:1413-1423.
101. van der Does R, Euler R. A randomized, double-blind, parallel-group study to compare the antihypertensive effects of imidapril and nifedipine in the treatment of mild-to-moderate essential hypertension. J Int Med Res 2001; 29:154-162. (Pubitemid 32655211)
102. Van Nueten L, Lacourciere Y, Vyssoulis G, Korlipara K, Marcadet DM, Dupont AG, et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther 1998; 5:237-243. (Pubitemid 28373710)
103. Viskoper RJ, Bernink PJ, Schelling A, Ribeiro AB, Kantola IM, Wilkins MR, et al. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group. J Hum Hypertens 1997; 11:387-393. (Pubitemid 27354963)
104. Volpe M, Junren Z, Maxwell T, Rodriguez A, Gamboa R, Gomez- Fernandez P, et al. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther 2003; 25:1469-1489. (Pubitemid 36677288)
105. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009; 29:11-25.
106. Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18:411-428. (Pubitemid 26248901)
107. Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley W, Zelenkofske S. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 2005; 46:508-513. (Pubitemid 41376830)
108. Wester A, Lorimer AR, Westberg B. Felodipine extended release in mild to moderate hypertension. Curr Med Res Opin 1991; 12:275-281.
109. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41:1021-1026. (Pubitemid 36548598)
110. White WB, Lacourciere Y, Gana T, Pascual MG, Smith DH, Albert KS. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. Am Heart J 2004; 148:628-634. (Pubitemid 39349382)
111. Wright JT Jr, Sica DA, Gana TJ, Bohannon K, Pascual LG, Albert KS. Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. Am J Hypertens 2004; 17:734-742. (Pubitemid 39201086)
112. Zannad F, Boivin JM. Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group. J Hypertens 1999; 17:1023-1032. (Pubitemid 29322192)
113. Zidek W, Spiecker C, Knaup G, Steindl L, Breuer HW. Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group. Clin Ther 1995; 17:686-700.
114. Messerli FH, Grossman E. Pedal edema: not all dihydropyridine calcium antagonists are created equal. Am J Hypertens 2002; 15:1019-1020. (Pubitemid 35217412)
115. Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens 2001; 15:455-461. (Pubitemid 32640260)
116. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14 (9 Pt 1):963-968. (Pubitemid 32862599)
117. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blockerassociated peripheral edema. Am J Med 2011; 124:128-135.
118. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl 1998; 2:10-17. (Pubitemid 28529748)
119. Ohtsuka M, Yokota M, Kodama I, Yamada K, Shibata S. New generation dihydropyridine calcium entry blockers: in search of greater selectivity for one tissue subtype. Gen Pharmacol 1989; 20:539-556. (Pubitemid 19232586)
120. Fogari R, Malamani G, Zoppi A, Mugellini A, Rinaldi A, Fogari E, et al. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther 2007; 29:413-418. (Pubitemid 46907281)